TY - JOUR
T1 - The Experience with Cytotoxic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
AU - Eisenberger, Mario A.
AU - Antonarakis, Emmanuel S.
PY - 2012/11
Y1 - 2012/11
N2 - This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
AB - This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
KW - Cytotoxic chemotherapy
KW - Docetaxel
KW - Metastatic castration-resistant prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84867665334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867665334&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2012.07.012
DO - 10.1016/j.ucl.2012.07.012
M3 - Review article
C2 - 23084532
AN - SCOPUS:84867665334
SN - 0094-0143
VL - 39
SP - 573
EP - 581
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
IS - 4
ER -
